Forbes Medi-Tech (FMTI) to Sell Pharmaceutical Assets to Transition Therapeutics (TTHI)
More News related to FMTI
- Forbes Medi-Tech (FMTI) Reports a Q3 Loss; Withdraws FY08 Revenue Guidance
- Forbes Medi-Tech Announces Third Quarter 2008 Financial Results
- Forbes Medi-Tech Announces Third Quarter 2008 Financial Results
- Forbes Medi-Tech Receives Extension to Compliance Deadline
- Forbes Medi-Tech Receives Extension to Compliance Deadline
More News related to TTHI
- Transition Therapeutics Announces Dates for Upcoming Corporate Events
- Stem Cell Therapeutics Corp. Announces Third Quarter 2008 Financial Results and Provides Corporate Update
- Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
- Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
More News related to Mergers and Acquisitions
- Sources Say 'Highly Unlikely' That Miller Buys Yahoo! (YHOO) -CNBC
- Former AOL CEO John Miller In Talks With PE Shops To Buy Yahoo (YHOO)
- Reports Total Is Preparing A Bid For NEXEN (NXY)
- Bucyrus (BUCY) Completes Acquisition of Bastro a.s.
- LHC Group (LHCG) Completes Acquisitions of Whispering Pines Health Services and HomeCall; Guides FY09 Sales, EPS
Forbes Medi-Tech Inc. (NASDAQ: FMTI) announced today the sale of its pharmaceutical assets and business unit based in San Diego, California to Transition Therapeutics Inc. (NASDAQ: TTHI).
Terms of the sale include an upfront payment of $1 million in cash paid at closing to Forbes along with potential future payments of up to $6 million, in cash or Transition shares, based upon Transition reaching certain developmental and regulatory milestones as outlined in the agreement.
Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of products for the prevention and treatment of life-threatening diseases.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.01
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
